Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Diagnostic ultrasound performed by a physician as a dialog (2018) Strobel D, Meng S Journal article, Editorial Contrast-Enhanced µCT for Visualizing and Evaluating Murine Intestinal Inflammation (2018) Jung D, Heiß R, Kramer V, Thoma OM, Regensburger A, Rascher W, Uder M, et al. Journal article Detection by flow cytometry of anti-neutrophil cytoplasmic antibodies in a novel approach based on neutrophil extracellular traps (2018) Roitsch S, Goesswein S, Neurath M, Leppkes M Journal article Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients (2018) Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, et al. Conference contribution Alpha 4 beta 7 Integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages (2018) Schleier L, Wiendl M, Binder MT, Atreya R, Watson A, Neufert C, Atreya I, et al. Conference contribution Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens (2018) Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel ME Conference contribution The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis (2018) Schmitt H, Billmeier U, Ulmschneider J, Admyre C, Knittel T, Zargari A, Neurath M, Atreya R Conference contribution Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study (2018) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial (2018) Pavel ME, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, et al. Journal article